The Silent Half of Herbal Therapeutics: Herb–Drug Interactions and the Structural Invisibility of AYUSH Pharmacovigilance in India

Concurrent use of AYUSH preparations and conventional medicines is an ordinary feature of Indian clinical practice, yet it is almost never recorded in the medical chart. Hospital surveys from several states report that a majority of patients taking traditional medicines alongside prescribed drugs do not tell the treating physician, and that physicians rarely ask. A large, chronic and unmeasured exposure therefore sits underneath routine pharmacotherapy. This review argues that the resulting blind spot is structural rather than attitudinal, and identifies four mechanisms that sustain it. First, herbal exposure has no designated place in the admission medication history, so it goes unrecorded even when it is disclosed. Second, the suspected product cannot be pinned down: polyherbal and herbo-mineral formulations vary between manufacturers and between batches, and some carry metallic constituents by design. Third, causality instruments validated for single-molecule drugs perform poorly against multi-constituent preparations, where rechallenge is seldom feasible and the offending constituent is rarely identifiable. Fourth, India operates two pharmacovigilance architectures, one for conventional drugs and one for ASU&H medicines, with no shared product identifier and no common reporting pathway, so an event arising at the interface belongs to neither. We further show that the herb–drug interaction evidence cited in Indian practice is drawn largely from species with limited relevance to Indian prescribing. We propose a three-tier, ward-level model — Capture, Characterise, connect — that places the clinical pharmacist and the AYUSH physician in a shared workflow, and set out what each tier would require. Keywords: herb–drug interactions; AYUSH; pharmacovigilance; medication reconciliation; clinical pharmacy; Ayurveda; patient safety

Authors

Publication Details

Journal
Zenodo (CERN European Organization for Nuclear Research)
Published
2026-11-20
DOI
https://doi.org/10.5281/zenodo.24387408
Primary Topic
Complementary and Alternative Medicine Studies
Type
article
Field-Weighted Citation Impact
0.00
Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
NOV
article

The Silent Half of Herbal Therapeutics: Herb–Drug Interactions and the Structural Invisibility of AYUSH Pharmacovigilance in India

Pallavi A. Hegde, Raghavendra Shivaram Hegde, Subhasis Mishra
1 links
Zenodo (CERN European Organization for Nuclear Research)
Complementary and Alternative Medicine Studies
article

The Silent Half of Herbal Therapeutics: Herb–Drug Interactions and the Structural Invisibility of AYUSH Pharmacovigilance in India

Pallavi A. Hegde, Raghavendra Shivaram Hegde, Subhasis Mishra
article en

Abstract

Concurrent use of AYUSH preparations and conventional medicines is an ordinary feature of Indian clinical practice, yet it is almost never recorded in the medical chart. Hospital surveys from several states report that a majority of patients taking traditional medicines alongside prescribed drugs do not tell the treating physician, and that physicians rarely ask. A large, chronic and unmeasured exposure therefore sits underneath routine pharmacotherapy. This review argues that the resulting blind spot is structural rather than attitudinal, and identifies four mechanisms that sustain it. First, herbal exposure has no designated place in the admission medication history, so it goes unrecorded even when it is disclosed. Second, the suspected product cannot be pinned down: polyherbal and herbo-mineral formulations vary between manufacturers and between batches, and some carry metallic constituents by design. Third, causality instruments validated for single-molecule drugs perform poorly against multi-constituent preparations, where rechallenge is seldom feasible and the offending constituent is rarely identifiable. Fourth, India operates two pharmacovigilance architectures, one for conventional drugs and one for ASU&H medicines, with no shared product identifier and no common reporting pathway, so an event arising at the interface belongs to neither. We further show that the herb–drug interaction evidence cited in Indian practice is drawn largely from species with limited relevance to Indian prescribing. We propose a three-tier, ward-level model — Capture, Characterise, connect — that places the clinical pharmacist and the AYUSH physician in a shared workflow, and set out what each tier would require. Keywords: herb–drug interactions; AYUSH; pharmacovigilance; medication reconciliation; clinical pharmacy; Ayurveda; patient safety

Zenodo (CERN European Organization for Nuclear Research)
Good health and well-being
Complementary and Alternative Medicine Studies
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.

Laika access coming soon
The Silent Half of Herbal Therapeutics: Herb–Drug Interactions and the Structural Invisibility of AYUSH Pharmacovigilance in India — Pallavi A. Hegde, Raghavendra Shivaram Hegde, et al. · Zenodo (CERN European Organization for Nuclear Research) (2026) | TGRS Research Map | TGRS